Loading clinical trials...

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population | Clinical Trials | Clareo Health

COMPLETEDNA

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population : Pilot Project PARKA

NCT04322461•Université de Sherbrooke

View on ClinicalTrials.gov

Summary

A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.

Eligibility

Age

60 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Alzheimer's or parkinson disease diagnostic
•Stable medication associated with the disease
•Able to consent
•Presence of an accompanying person for the first and last visit.
•Ability to read and talk in French

Exclusion Criteria

•MMSE \< 20
•MCT or coconut oil supplementation
•Coconut allergy
•Cannabis, THC or CBD consumption
•Excessive alcohol consumption
•Physical activity 3x/week
•Presence of an metallic object in the body
•Impossibility to lay in dorsal decubitus for 40 minutes
•Cardiac disease
•Any uncontrolled disease that could interfer with the project.

Locations (1)

Centre de recherche sur le vieillissement

Sherbrooke, Quebec, Canada

Key Dates

Start Date

May 1, 2022

Primary Completion Date

May 27, 2024

Completion Date

May 27, 2024

Last Updated

June 3, 2025

Enrollment

ACTUAL participants

Conditions

Parkinson DiseaseAlzheimer Disease

Interventions

Betaquik MCT supplement

DIETARY_SUPPLEMENT

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Montelukast in Parkinson Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)